Innate Pharma (IPHA) Set to Announce Quarterly Earnings on Tuesday

Innate Pharma (NASDAQ:IPHA - Get Free Report) is scheduled to post its quarterly earnings results before the market opens on Tuesday, May 14th. Individual that are interested in registering for the company's earnings conference call can do so using this link.

Innate Pharma Trading Up 2.3 %

NASDAQ IPHA traded up $0.06 during trading on Wednesday, hitting $2.63. The company's stock had a trading volume of 546 shares, compared to its average volume of 10,074. Innate Pharma has a 52 week low of $1.81 and a 52 week high of $3.57. The company has a debt-to-equity ratio of 0.60, a quick ratio of 3.73 and a current ratio of 3.73. The firm has a 50 day moving average price of $2.52 and a 200 day moving average price of $2.55.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and set a $11.50 target price on shares of Innate Pharma in a research note on Thursday, April 11th.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.